Triveni Bio has dosed the first healthy volunteers in its Phase I study of TRIV-573, a half-life extended bispecific antibody aimed at kallikreins 5 and 7 (KLK5/7) and interleukin 13 (IL-13).
With the ongoing changes in atopic dermatitis (AD) treatment, TRIV-573’s dual-targeting of KLK5/7 and IL-13 aims to address both skin barrier dysfunction and inflammation.
The trial investigates a combination approach that uses KLK5/7 inhibition for barrier repair alongside IL-13 blockade for anti-inflammatory effect, which seeks to meet unmet needs in moderate-to-severe AD.
Triveni Bio chief medical officer Bhaskar Srivastava said: “TRIV-573 builds on compelling preclinical evidence that KLK5/7 inhibition addresses all three pillars of AD pathology: barrier, inflammation, and itch.
“We have demonstrated preclinical additivity when combining the KLK5/7 mechanism with Th2 targeting, positioning TRIV-573 as a novel combination approach for moderate-to-severe AD with a single therapeutic designed for infrequent, patient-friendly dosing.”
The Phase I trial launch extends Triveni Bio’s clinical pipeline, with plans to advance towards a Phase II proof-of-concept study in the second half of 2026.
The company develops genetics-informed antibody therapies for immunological and inflammatory (I&I) disorders.
Triveni Bio CEO Vishal Patel said: “Advancing TRIV-573 into the clinic less than one year after TRIV-509 is a testament to our team’s execution.
“We are thrilled to progress this unique therapy as we work to break the existing efficacy ceiling for patients with AD and other I&I disorders.”
Triveni Bio’s lead programme, TRIV-509 (anti-KLK5/7), is being studied in an ongoing Phase II trial for moderate-to-severe AD, with results expected at the end of 2026.
